KRT7 and pancreatic adenocarcinoma: In our study, 77.5% of pancreatic adenocarcinomas, 50% of gastric adenocarcinomas, 85.7% of lung adenocarcinomas, and 64.3% of breast carcinomas exhibited a CK7+ CK20- immunophenotype.